Video Experimental Relacionado
Updated: Mar 1, 2026
07:41
A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
9.6K
Avances recientes y perspectivas de los moduladores de moléculas pequeñas dirigidos a DOT1L
Qiangsheng Zhang1, You Huang1, Mengling Yang1
1School of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, P. R. China.
Journal of medicinal chemistry
|February 28, 2026
Resumen
El disruptor del silenciamiento telomérico 1-like (DOT1L) es una enzima clave en el desarrollo celular y enfermedades como la leucemia aguda. La focalización de DOT1L con nuevos moduladores ofrece oportunidades terapéuticas para diversas afecciones.
Área de la Ciencia:
- Bioquímica
- Biología Molecular
- Oncología
Sus antecedentes:
- DOT1L es la única HMT para H3K79, crucial para la regulación génica.
- Impacta la renovación de células madre, la diferenciación de células B y el desarrollo neuronal.
- La actividad aberrante de DOT1L impulsa la leucemia mieloide aguda (LMA) reordenada por MLL al activar oncogenes como HOXA9.
Objetivo del estudio:
- Revisar el papel de DOT1L en la patogénesis de la enfermedad.
- Discutir el desarrollo de moduladores de DOT1L.
- Proporcionar información para futuras terapias dirigidas a DOT1L.
Principales métodos:
- Revisión de la literatura existente sobre DOT1L.
- Análisis de las funciones enzimáticas y no enzimáticas de DOT1L.
- Discusión de estrategias farmacológicas dirigidas a DOT1L.
Principales resultados:
- Se confirman los roles críticos de DOT1L en el desarrollo normal y las enfermedades.
- Se han desarrollado varios moduladores (inhibidores, degradadores) dirigidos a DOT1L.
- La expresión anormal, las mutaciones y las interacciones de DOT1L contribuyen a la enfermedad.
Conclusiones:
- DOT1L es un objetivo terapéutico validado para enfermedades, incluida la LMA.
- Se están explorando diversos enfoques farmacológicos para inhibir DOT1L.
- La investigación adicional sobre moduladores de DOT1L es prometedora para nuevos tratamientos.
Videos de Conceptos Relacionados
01:26Targets for Drug Action: Overview
10.8K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.8K
01:24Principles of Drug Action
9.1K
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
9.1K
01:29Pharmacogenomics: Identification of New Drug Targets
53
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
53
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
62
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
62
01:21Pharmacodynamics: Overview and Principles
3.7K
Pharmacodynamics is a scientific field that delves into drugs' intricate biochemical, cellular, and physiological effects on the human body. The study of pharmacodynamics helps us understand how drugs interact with the body and elicit various responses.
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
3.7K
01:24Modified-Release Drug Delivery Systems: Site-Targeted
51
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
51